Characterization and predictors of sleep disturbance in patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

被引：0
|
作者：
Westbrook, Travis D.
Maddocks, Kami J.
Andersen, Barbara L.
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18021
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    HAEMATOLOGICA, 2014, 99 : 589 - 589
  • [22] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [23] Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Wierda, William G.
    Dorritie, Kathleen A.
    Munoz, Javier
    Stephens, Deborah M.
    Solomon, Scott R.
    Gillenwater, Heidi H.
    Gong, Lucy
    Yang, Lin
    Ogasawara, Ken
    Thorpe, Jerill
    Siddiqi, Tanya
    BLOOD, 2020, 136
  • [24] Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
    Siddiqi, Tanya
    Gauthier, Jordan
    Kenderian, Saad S.
    Brander, Danielle M.
    Dorritie, Kathleen
    Soumerai, Jacob D.
    Reidell, Peter A.
    Shah, Nirav N.
    Nath, Rajneesh
    Andreadis, Charalambos
    Ermann, Daniel A.
    Ma, Shuo
    Feldman, Tatyana
    Solomon, Scott R.
    Schuster, Stephen J.
    Tuazon, Sherilyn A.
    Perna, Serena K.
    Ou, San-San
    Rane, Neha
    Papp, Eniko
    Chen, Yizhe
    Wierda, William G.
    BLOOD, 2024, 144 : 4633 - 4635
  • [25] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [26] ANALYSIS OF TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Sallum, R.
    Dorman, E.
    Xu, Y.
    Tran-Kerr, K.
    O'Donnell, M.
    Sorensen, S.
    Szatkowski, A.
    Sengupta, N.
    Gaudig, M.
    VALUE IN HEALTH, 2014, 17 (07) : A616 - A616
  • [27] Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Roberts, Andrew W.
    Ma, Shuo
    Brander, Danielle M.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Tam, Constantine
    Mason-Bright, Tanita
    Rudersdorf, Nikita K.
    Gressick, Lori
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Seymour, John F.
    BLOOD, 2014, 124 (21)
  • [28] Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up
    Woyach, Jennifer A.
    Rogers, Kerry A.
    Bhat, Seema
    Blachly, James
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min Hui
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S281 - S281
  • [29] SINGLE-AGENT IBRUTINIB VS STANDARD OF CARE FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE™ WITH THE CLLEAR DATABASE
    Doubek, M.
    Obrtlikova, P.
    Spacek, M.
    Urbanova, R.
    Diels, J.
    Thilakaratne, P.
    Musingarimi, P.
    Mac Dougall, F.
    Hermans, R.
    Barendse, M.
    Iraqi, W.
    Smolej, L.
    HAEMATOLOGICA, 2016, 101 : 230 - 231
  • [30] COST-MINIMIZATION ANALYSIS (CMA) OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN ADULTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Chanan-Khan, A.
    Mohseninejad, L.
    Walder, L.
    Ubi, S.
    Gani, R.
    Shah, A.
    Yang, K.
    VALUE IN HEALTH, 2023, 26 (12) : S182 - S182
12345